TC Biopharm (Holdings) Plc (TCBP) Stock Analysis

TC Biopharm (Holdings) Plc (TCBP) Healthcare & Pipeline Overview

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical firm developing allogeneic gamma delta T cell therapies, including OmnImmune for acute myeloid leukemia and ImmuniStim for COVID-19. Founded in 2013 and based in the UK, TCBP operates within the competitive biotechnology sector, focusing on innovative immunotherapy solutions.

What Is the Investment Thesis for TCBP?

TC Biopharm presents a high-risk, high-reward investment profile typical of clinical-stage biotechnology companies. The company's allogeneic gamma delta T cell platform represents a novel approach to immunotherapy, with the potential to address significant unmet needs in oncology and infectious diseases. Key value drivers include the successful clinical development and regulatory approval of OmnImmune for AML and ImmuniStim for COVID-19. Upcoming clinical trial results for OmnImmune will be a critical catalyst. However, the company faces significant challenges, including the inherent risks associated with drug development, regulatory hurdles, and the need to secure substantial additional funding to advance its pipeline. With a market capitalization of $0.00B, TC Biopharm's valuation is highly sensitive to clinical trial outcomes and regulatory decisions.

Based on FMP financials and quantitative analysis

TCBP Key Highlights

TC Biopharm is a clinical-stage biopharmaceutical company focused on allogeneic gamma delta T cell therapies.

• The company's lead product candidate, OmnImmune, targets acute myeloid leukemia (AML).
• ImmuniStim, another key product, is being developed for the treatment of COVID-19.
• TC Biopharm's technology platform leverages the unique properties of gamma delta T cells.
• The company is headquartered in Motherwell, United Kingdom, and employs 41 people.

Who Are TCBP's Competitors?

TCBP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TCBP's Key Strengths?

Novel allogeneic gamma delta T cell platform.

• Potential for broad application across multiple diseases.
• Experienced management team.
• Focus on unmet medical needs.

What Are TCBP's Weaknesses?

Clinical-stage company with no approved products.

• Limited financial resources.
• High dependence on clinical trial outcomes.
• Competition from larger pharmaceutical companies.

What Could Drive TCBP Stock Higher?

Clinical trial results for OmnImmune in acute myeloid leukemia (AML).

• Regulatory submissions for OmnImmune and ImmuniStim.
• Expansion of the gamma delta T cell platform to new indications.
• Strategic partnerships and collaborations with pharmaceutical companies.
• Securing additional funding to support clinical development.

What Are the Key Risks for TCBP?

Financial-distress signal — its Altman Z-Score of -14.68 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for OmnImmune and ImmuniStim.
• Regulatory hurdles and delays in obtaining approvals.
• Competition from other immunotherapy companies.
• Inability to secure sufficient funding to advance the pipeline.
• Intellectual property challenges and patent disputes.

What Are the Growth Opportunities for TCBP?

• Advancement of OmnImmune for AML: TC Biopharm's lead product candidate, OmnImmune, represents a significant growth opportunity in the treatment of acute myeloid leukemia (AML). Successful clinical trials and regulatory approval could drive substantial revenue growth for TC Biopharm. The timeline for this growth opportunity is dependent on clinical trial progress, with key milestones expected over the next 2-3 years.
• Development of ImmuniStim for COVID-19: ImmuniStim, TC Biopharm's cell therapy for COVID-19, offers another growth avenue. While the pandemic's acute phase has subsided, the need for effective treatments for immunocompromised individuals and long COVID remains. Positive clinical data and regulatory approval could lead to a valuable revenue stream. The timeline for this opportunity depends on clinical trial outcomes and regulatory pathways.
• Expansion of Gamma Delta T Cell Platform: TC Biopharm's allogeneic gamma delta T cell platform has the potential to be applied to a wider range of diseases beyond AML and COVID-19. Expanding the platform to target other cancers and infectious diseases could unlock significant growth opportunities. This expansion would require further research and development, with a longer-term timeline of 3-5 years.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could accelerate the development and commercialization of TC Biopharm's products. These partnerships could provide access to funding, expertise, and distribution channels, driving growth and reducing risk. The timeline for this opportunity is variable, depending on the availability of suitable partners.
• Geographic Expansion: Expanding into new geographic markets, such as the United States and Europe, could significantly increase TC Biopharm's revenue potential. This expansion would require regulatory approvals and the establishment of commercial infrastructure. The timeline for this opportunity is dependent on regulatory pathways and market entry strategies, with a potential timeframe of 2-4 years.

What Are TCBP's Competitive Advantages?

• Proprietary allogeneic gamma delta T cell platform.
• Intellectual property protection for their therapies.
• Clinical data supporting the safety and efficacy of their products.
• Expertise in gamma delta T cell biology and immunotherapy development.

What Does TCBP Do?

Founded in 2013 and headquartered in Motherwell, United Kingdom, TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapy products. The company's core technology revolves around its allogeneic gamma delta T cell platform, which it believes holds significant potential for treating a variety of diseases. TC Biopharm's lead product candidates include OmnImmune, an unmodified cell therapy targeting acute myeloid leukemia (AML), and ImmuniStim, another unmodified cell therapy being developed for the treatment of COVID-19. These therapies leverage the unique properties of gamma delta T cells, a type of immune cell that can recognize and kill cancer cells and virally infected cells. The company is focused on advancing its clinical programs and expanding its pipeline of gamma delta T cell-based immunotherapies to address unmet medical needs in oncology and infectious diseases. TC Biopharm is committed to translating its scientific discoveries into effective treatments for patients.

What Products and Services Does TCBP Offer?

• Develop allogeneic gamma delta T cell-based immunotherapies.
• Focus on treatments for acute myeloid leukemia (AML) and COVID-19.
• Utilize a proprietary technology platform to harness the power of gamma delta T cells.
• Conduct clinical trials to evaluate the safety and efficacy of their therapies.
• Seek regulatory approvals for their products from health authorities.
• Engage in research and development to expand their pipeline of immunotherapies.

How Does TCBP Make Money?

• Develop and commercialize allogeneic gamma delta T cell therapies.
• Generate revenue through product sales following regulatory approval.
• Potentially generate revenue through licensing agreements and partnerships.
• Secure funding through venture capital, public offerings, and grants.

What Industry Does TCBP Operate In?

TC Biopharm operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. The immunotherapy market, in particular, is experiencing significant growth, driven by the increasing prevalence of cancer and infectious diseases, as well as advances in cell and gene therapies. TC Biopharm's allogeneic gamma delta T cell platform positions it within this growing market, competing with other companies developing cell-based immunotherapies. Competitors include companies like BioLineRx (BLPH), Histogenics Corporation (HSTO), Immatics N.V. (IMTX), Leafly Holdings (LFLY), and LSB Industries (LSB).

Who Are TCBP's Key Customers?

• Hospitals and cancer centers treating patients with AML.
• Healthcare providers treating patients with COVID-19.
• Patients suffering from AML and COVID-19.
• Potential pharmaceutical partners seeking innovative immunotherapies.

Key Financial Metrics

Return on assets is -66.1%, showing how much profit it generates from its asset base. A current ratio of 1.20 indicates the company holds enough short-term assets to cover its near-term obligations.

Company Profile

TC Biopharm (Holdings) Plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Motherwell, GB. The company is led by CEO Bryan Leland Kobel. TCBP has traded publicly since 2022.

TC Biopharm (Holdings) Plc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.68 places it in the distress zone, a signal of elevated financial risk.

The most recent 12 insider filings for TC Biopharm (Holdings) Plc break down as 0 sales and 12 purchases. On net that is roughly 840K shares acquired (about $3.1M) — insiders putting money in tends to read as conviction.

TCBP Financials

TCBP Latest News

TC Biopharm (Holdings) Plc Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources